
## Ashraf Reda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9294990/publications.pdf Version: 2024-02-01



ACHDAE DEDA

#	Article	IF	CITATIONS
1	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
2	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
3	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology, 2020, 5, 217.	6.1	169
4	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
5	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
6	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	4.1	94
7	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
8	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
9	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
10	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
11	Clinical characteristics and management of hospitalized and ambulatory patients with heart failure–results from ESC heart failure longâ€term registry–Egyptian cohort. ESC Heart Failure, 2015, 2, 159-167.	3.1	34
12	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
13	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
14	Gender differences in <scp>Egyptian</scp> patients hospitalized with heart failure: insights from the <scp>European Society of Cardiology Heart Failure Longâ€Term Registry</scp> . ESC Heart Failure, 2018, 5, 1159-1164.	3.1	15
15	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
16	The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross-sectional CardioRisk project. Cardiovascular Journal of Africa, 2019, 30, 87-94.	0.4	13
17	Taq 1B polymorphism of cholesteryl ester transfer protein (CETP) in Egyptian patients with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2011, 5, 61-65.	3.6	9
18	Assessment of left atrial deformation properties by speckle tracking in patients with systolic heart failure. Egyptian Heart Journal, 2015, 67, 199-208.	1.2	7

Ashraf Reda

#	Article	IF	CITATIONS
19	Relationship of apolipoprotein E polymorphism with lipid profiles in atherosclerotic coronary artery disease. Egyptian Heart Journal, 2013, 65, 71-78.	1.2	6
20	The Egyptian cardiovascular risk factors project, phase (II) results: A multicenter observational study of the pattern of risk factor profile in Egyptian patients with acute coronary syndrome. Atherosclerosis, 2017, 263, e159.	0.8	4
21	Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Egyptian Heart Journal, 2020, 72, 23.	1.2	4
22	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and Therapy, 2017, 6, 105-120.	2.6	3
23	Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2021, 41, 1027-1036.	2.2	3
24	Gender-related Differences in Risk factors and Treatment Strategies in Patients with Acute Coronary Syndrome across Egypt: part of the Cardio- Risk Project. Atherosclerosis Supplements, 2018, 33, e2.	1.2	2
25	A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes. Journal of the Egyptian Public Health Association, The, 2021, 96, 32.	2.5	2
26	Assessment of diastolic reserve in hypertensive patients by dobutamine stress Doppler tissue imaging. Egyptian Heart Journal, 2015, 67, 13-20.	1.2	1
27	Right ventricular function and symptomatology in patients with isolated mitral stenosis: A Doppler tissue imaging study. Egyptian Heart Journal, 2015, 67, 41-46.	1.2	1
28	Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndrome: final data of the nationwide cross-sectional â€~CardioRisk' project. Journal of Public Health in Africa, 2020, 11, 1368.	0.4	1
29	Estimated Prevalence of Familial Hypercholesterolemia Among Egyptian Patients with Acute Coronary Syndromes; Analysis from The Cardiorisk Project. European Heart Journal Supplements, 2021, 23, .	0.1	1
30	Clinical Characteristics, Laboratory Profiles, And Treatment Modalities for Familial Hypercholesterolemia in Egypt. European Heart Journal Supplements, 2021, 23, .	0.1	1
31	Cardiovascular Risk Factors in a sample of Egyptian population with Acute Coronary Syndrome: part of a Multi-centre Observational study: preliminary data of the pilot phase of the Egyptian Cardiorisk project. Atherosclerosis Supplements, 2018, 33, e3.	1.2	0
32	Pilot phase of the Egyptian Familial hypercholesterolemia Research Forum Registry. Atherosclerosis Supplements, 2018, 33, e3.	1.2	0
33	Safety and Efficacy of Drug-Eluting Balloon Angioplasty in Patients with Peripheral Arterial Diseases: A Prospective study. Atherosclerosis Supplements, 2018, 33, e4.	1.2	0
34	A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America. Advances in Therapy, 2020, 37, 1754-1777.	2.9	0
35	Egyptian Association of Vascular Biology and Atherosclerosis Consensus on The Usage of SGLT2 Inhibitors in Heart Failure. European Heart Journal Supplements, 2021, 23, .	0.1	0